Holen Sie sich die Stockscreener-App
1.75
3.01%
-0.08
Schlusskurs vom Vortag:
$1.83
Offen:
$1.8
24-Stunden-Volumen:
39,491
Relative Volume:
0.62
Marktkapitalisierung:
$164.33M
Einnahmen:
$3.13M
Nettoeinkommen (Verlust:
$-55.77M
KGV:
-2.8478
EPS:
-0.6145
Netto-Cashflow:
$-61.24M
1W Leistung:
-12.56%
1M Leistung:
+25.89%
6M Leistung:
-6.08%
1J Leistung:
-17.82%
1-Tages-Spanne:
$1.72
$1.83
1-Wochen-Bereich:
$1.72
$2.2971
52-Wochen-Spanne:
$1.17
$2.63
Innate Pharma Adr Stock (IPHA) Company Profile
Firmenname
Innate Pharma Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare IPHA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.75 | 171.84M | 3.13M | -55.77M | -61.24M | -0.6145 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2025-09-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-18 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-28 | Eingeleitet | BTIG Research | Buy |
| 2021-09-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Innate Pharma Adr Aktie (IPHA) Neueste Nachrichten
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations - Investing.com
Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target - TipRanks
Innate Pharma Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts - Investing.com
Unusual VolumeStock ScreenerNews - Finviz
Innate Pharma reports interim lung cancer trial results By Investing.com - Investing.com South Africa
Innate Pharma reports interim lung cancer trial results - Investing.com
HC Wainwright Decreases Earnings Estimates for Innate Pharma - MarketBeat
Top GainersStock ScreenerSnapshot - Finviz
Innate Pharma (IPHA) outlines oncology pipeline and key risks in Form 20-F - Stock Titan
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest - MarketBeat
Innate Pharma Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management - Investing.com India
Innate Pharma reports 55% revenue drop, expects cash runway until end of Q3 2026 - Investing.com
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update - MarketBeat
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline By Investing.com - Investing.com India
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline - Investing.com
NASDAQ New 52-Week Highs And Lows - Moomoo
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6% – Here’s What Happened - Defense World
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference - ChartMill
Innate Pharma (NASDAQ:IPHA) Stock Price Down 2.2%Should You Sell? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Down 0.5%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3% – Should You Buy? - Defense World
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3%Should You Buy? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Up 3.7%Should You Buy? - MarketBeat
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress By Investing.com - Investing.com UK
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - Investing.com
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Should I buy Innate Pharma (IPHA) - Zacks Investment Research
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com
Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential By Investing.com - Investing.com South Africa
TuHURA Biosciences (HURA) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Let's take a look at the stocks that are in motion in today's session. - ChartMill
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Earnings call: Innate Pharma reports progress in drug development - Investing.com
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Innate Pharma (IPHA) Stock Forecast and Price Target 2026 - MarketBeat
Innate Pharma Announces Its Participation in Upcoming Investor Conference By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Nasdaq
What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research
Which Is a Better Investment, Novo Nordisk A/S (ADR) or Sanofi SA (ADR) Stock? - AAII
Finanzdaten der Innate Pharma Adr-Aktie (IPHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):